FDA Names New Leaders for Drugs, Vaccines, Tobacco and AI

Washington – In a move that should bring a sigh of relief to a jittery Food and Drug Administration, the Trump administration announced Tuesday that four top‑level vacancies have finally been filled. The appointments convert several long‑standing acting officials into permanent directors, giving the agency a steadier footing after a whirlwind of resignations and controversies earlier this year.

Leading the FDA’s biggest arm, the Center for Drug Evaluation and Research, is Dr. Michael Davis. Davis, who stepped into the role after Dr. Tracy Beth Hoeg’s abrupt dismissal in May, has a background in psychiatric‑drug regulation and even a stint at a nonprofit focused on psychedelic therapeutics. As the new chief drug regulator, he’ll now steer the review of a wave of experimental psychedelics – psilocybin, MDMA, LSD – that the White House says should move faster through the approval pipeline.

Taking over the Center for Biologics Evaluation and Research, which includes vaccines, is veteran pharmacist Karim Mikhail. Mikhail joined the FDA last spring and filled the acting slot after Dr. Vinay Prasad walked away amid heated debates over COVID‑19 boosters, gene therapies and rare‑disease drugs. His appointment signals a return to a more traditional, industry‑savvy leadership style for the vaccine office.

Over at the Center for Tobacco Products, career FDA attorney Bret Koplow is now the permanent director. Koplow had been holding the fort since the previous director was ousted early in the administration. Under his watch, the agency has already cleared several new nicotine‑pouch and e‑cigarette products, a sign that the FDA is finally making headway on the vaping‑flavor controversy that sparked protests from both anti‑vaping activists and tobacco lobbyists.

Rounding out the quartet is Jared Seehafer, appointed to a brand‑new position that will oversee artificial‑intelligence and technology initiatives across the FDA. The role reflects the agency’s growing interest in leveraging AI for everything from drug‑review algorithms to post‑market surveillance.

Together, these four appointments should restore some continuity to an agency that has been on shaky ground for months. Consumer groups, medical professionals and congressional Democrats will be watching closely to see whether the new leaders can balance rapid innovation with the safety safeguards the FDA is famed for.